Key facts
- CND Life Sciences’s last known valuation is $30.5M (Mar 2023).
- It has raised $29.3M across 7 recorded rounds; the latest was Early Stage VC ($8.6M) in Feb 2025.
- Notable investors include Labcorp Venture Fund, MBX Capital, Cambrian Capital, Blue Stone Venture, BlueStone Venture Partners — 14 tracked in total.
- CND Life Sciences has filed 10 Form Ds with the SEC since 2021, most recently May 2025 ($8.6M sold to 38 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for CND Life Sciences
Funding rounds
7 roundsAbout CND Life Sciences
Developer of a medical diagnostic platform designed to detect key pathological markers in the peripheral nervous system. The company's platform detects, visualizes, and quantifies the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers and confirms synucleinopathy in patients with suspected Parkinson's disease, enabling medical experts with a convenient, accurate, minimally invasive alternative to aid in the diagnosis of neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Scottsdale, AZ, United States
- Founded
- 2017
- Employees
- 136
- Website
- cndlifesciences.com/
- Ownership
- Privately Held (backing)
CND Life Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CND Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CND Life Sciences in its N-PORT filings yet. We sweep new filings monthly.